Announcements Trials
Browse Landscape

Phase

Phase 3 15Phase NA 11Phase 1 11Phase 2/3 7Phase 2 5Phase 1/2 5Phase EARLY_PHASE1 4Phase 4 3

Status

Recruiting 7Unknown 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Conditions

Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Stomach Neoplasms 12Colorectal Neoplasms 12Breast Neoplasms 12Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Neoplasm Metastasis 9Lung Neoplasms 9Hematologic Neoplasms 9Head and Neck Neoplasms 9Endometrial Neoplasms 9Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Myasthenia Gravis 7Melanoma 7Uterine Cervical Neoplasms 6Recurrence 6Rectal Neoplasms 6Neoplasms by Site 6Neoplasms by Histologic Type 6Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Neoplasms, Plasma Cell 5Infections 5Colonic Neoplasms 5

Interventions

zilucoplan 1rozanolixizumab 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Myasthenia Gravis × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06055959 2026-05-08

ziMyG

UCB Pharma

Phase 2/3 Recruiting
8 enrolled

Myasthenia Gravis

NCT06149559 2026-05-08

roMyG

UCB Pharma

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT06447597 2026-04-30

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2/3 Recruiting
104 enrolled

Myasthenia Gravis

NCT06392386 2026-04-27

ADAPT Jr SC

argenx

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT05265273 2026-03-13

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Janssen Research & Development, LLC

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT04833894 2026-02-18

ADAPT Jr

argenx

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡